Institutional Habits Drive Extended-Release Opioid Use After Joint Replacement

The Persistence of Extended-Release Opioids in Postoperative Arthroplasty Care

Effective postoperative analgesia is essential for early mobilization and successful rehabilitation following total joint arthroplasty [1]. Multimodal strategies incorporating regional anesthesia, nonsteroidal anti-inflammatory drugs, and gabapentinoids have demonstrated efficacy, with nonsteroidal anti-inflammatory drugs and gabapentinoids reducing intravenous morphine consumption by an average of 9.30 mg and 10.89 mg respectively within the first 24 hours [2, 3]. Despite these benefits, clinical guidelines often discourage the use of specific interventions like intrathecal morphine (an analgesic injected into the spinal canal) because the associated nausea and vomiting can delay ambulation and interfere with same-day discharge protocols [4]. Non-pharmacological adjuncts also show utility, as cognitive behavioral therapy (a structured psychotherapy focusing on modifying negative thought patterns) significantly improves early postoperative pain scores on the visual analog scale at three months (p < 0.05) [5]. Nevertheless, prescribing habits for high-potency opioids remain inconsistent across institutions [6]. A new population-based analysis now examines the specific factors and institutional variations that drive the continued dispensing of extended-release opioids after hospital discharge.

Quantifying Post-Discharge Opioid Dispensing

The researchers conducted a population-based cross-sectional analysis (a study design that observes a population over a defined period to identify prevalence and associations) of adults undergoing primary total hip or knee arthroplasty between 2013 and 2022. To track patient outcomes and prescribing patterns, the study utilized linked administrative databases in Ontario, Canada. The final study cohort included 229,995 knee and hip arthroplasty procedures, providing a comprehensive dataset to evaluate how analgesic strategies have evolved in a large-scale clinical setting over a nine-year period. The primary outcome of the study was the fulfillment of an extended-release opioid (ERO) prescription within seven days of hospital discharge. Among the total procedures analyzed, 27,915 patients (12.1%) filled a new ERO prescription post-discharge. This data confirms that approximately one in ten patients fills an ERO prescription after total joint arthroplasty, a practice that continues despite clinical guidelines recommending against the use of long-acting opioid formulations for the management of acute postoperative pain. To identify the specific drivers behind these dispensing patterns, the authors employed multilevel logistic regression (a statistical method used to estimate associations between variables while accounting for data organized at multiple levels, such as patients nested within specific hospitals). This analysis allowed the researchers to estimate associations between patient, surgical, anesthetic, and hospital factors and the likelihood of ERO dispensing. By isolating these variables, the study sought to determine whether postoperative opioid selection is dictated by individual patient risk profiles or by broader institutional and surgical habits.

Clinical and Anesthetic Predictors of ERO Use

The researchers identified several patient-level characteristics that influenced the likelihood of receiving long-acting analgesics. Male sex was associated with increased odds of filling a new ERO prescription (OR 1.14, 95% CI 1.09-1.19), as was a higher baseline of medical complexity. Specifically, patients classified as American Society of Anesthesiologists (ASA) 3 status, which indicates the presence of severe systemic disease, had higher odds of ERO dispensing (OR 1.07, 95% CI 1.01-1.12). The study also utilized the Opioid Naïve-Exposed-Tolerant (ONET) score, a metric that categorizes patients based on their history of opioid use prior to surgery. The data showed a clear correlation between prior use and postoperative ERO fulfillment. Compared to opioid-naïve patients, those with an ONET Score of 2 (indicating moderate preoperative exposure) had increased odds of ERO dispensing (OR 1.21, 95% CI 1.15-1.27), while an ONET Score of 3 (indicating higher preoperative exposure) further increased the odds (OR 1.38, 95% CI 1.20-1.58). Anesthetic and perioperative management strategies played a significant role in mitigating the use of extended-release formulations. The use of neuraxial anesthesia, such as spinal or epidural techniques, was protective against filling a new ERO prescription (OR 0.79, 95% CI 0.74-0.84). Similarly, the administration of peripheral nerve blocks was associated with reduced odds of ERO dispensing (OR 0.84, 95% CI 0.79-0.89). Beyond specific procedural techniques, the involvement of an acute pain service, which is a specialized multidisciplinary team dedicated to optimizing postoperative analgesia, was also found to be protective against ERO dispensing (OR 0.77, 95% CI 0.70-0.85). These findings suggest that while certain patient factors like sex and preoperative opioid history increase the risk of ERO use, targeted anesthetic interventions and specialized pain management teams can effectively reduce the reliance on these medications during the transition to outpatient care.

The Dominance of Institutional and Surgical Variation

To determine why certain patients received extended-release opioids while others did not, the researchers quantified variation in prescribing using variance partition coefficients (a statistical measure representing the proportion of total variation attributable to a specific level of care, such as the hospital or the provider) and median odds ratios (the median increase in the odds of a patient receiving an extended-release opioid if they were treated at a different, higher-prescribing facility or by a different surgeon). These metrics, accompanied by 95% confidence intervals, allowed the study to distinguish between patient-driven needs and provider-driven habits. The analysis revealed that hospital-level variation was substantial, with a variance partition coefficient of 46% (95% CI 0.4-0.54) and a median odds ratio of 9.3 (95% CI 6.57-15.27). This indicates that the specific facility where a joint replacement is performed is a primary determinant of whether a patient is discharged with a long-acting opioid. The influence of the individual physician also played a major role, though it varied significantly by specialty. Surgeon-level variation was significant, showing a variance partition coefficient of 26% (95% CI 0.24-0.26) and a median odds ratio of 5.3 (95% CI 4.63-6.11). Conversely, the impact of the anesthesia provider was negligible; anesthetist-level variation was minimal, with a variance partition coefficient of 1% (95% CI 0.010-0.011) and a median odds ratio of 1.4 (95% CI 1.36-1.46). These data points suggest that while the surgical team and the institution's internal culture heavily influence prescribing, the specific anesthetist involved in the case has little bearing on the eventual fulfillment of an extended-release opioid prescription. Ultimately, the study found that patient-level factors explained only a minority of the observed variation in extended-release opioid dispensing. While clinical characteristics such as preoperative opioid exposure or comorbidities are often cited as justifications for more aggressive analgesia, the researchers concluded that extended-release opioid dispensing is predominantly driven by institutional and surgical practice patterns rather than individual patient clinical factors. For the practicing clinician, these findings highlight that the use of these medications may be more a reflection of local institutional habits and routine surgical protocols than a tailored response to the specific physiological needs or risk profiles of the patient.

Standardizing Discharge for Improved Stewardship

The finding that 12.1 percent of the 229,995 patients in this cohort filled an extended-release opioid prescription highlights a significant disconnect between clinical guidelines and real-world institutional practices. While major surgical societies generally recommend against the use of long-acting opioids for acute postoperative pain, the substantial hospital-level variation (variance partition coefficient 46 percent) and surgeon-level variation (variance partition coefficient 26 percent) suggest that local habits often supersede evidence-based recommendations. Because patient-level factors explained only a minority of the observed variation, the researchers emphasize that reducing unnecessary exposure to these high-potency medications requires a shift from individual clinician discretion toward systemic, facility-wide interventions. To address these disparities, the authors suggest that future research should focus on institutional stewardship, standardized discharge protocols, and multidisciplinary engagement. Institutional stewardship involves the implementation of formal programs within a hospital to monitor and optimize prescribing patterns, ensuring that analgesia aligns with current safety standards. Standardized discharge protocols (pre-established, uniform sets of postoperative orders and prescriptions) can help eliminate the wide variability seen between individual surgeons and facilities. Furthermore, the researchers advocate for multidisciplinary engagement, which involves collaborative decision-making between surgeons, anesthetists, and pharmacists to create a cohesive pain management plan that prioritizes non-opioid modalities and limits the use of extended-release formulations to exceptional cases.

References

1. Zhang L, Zhu F, Gao H, Zhang L, Quan R. Is intraoperative corticosteroid a good choice for postoperative pain relief in total joint arthroplasty? A meta-analysis of 11 randomized controlled trials.. Medicine. 2021. doi:10.1097/MD.0000000000027468

2. Syed IM, Al-Rubaie S, Cohen D, Slawaska-Eng D, Al-Besher M, Khanna V. Non-Opioid Analgesics for Postoperative Pain Management Following Total Joint Arthroplasty: A Systematic Review and Meta-Analysis.. The Journal of arthroplasty. 2025. doi:10.1016/j.arth.2025.03.027

3. Ibán MÁR, Oteo-Álvaro Á, Vázquez XM, Ávila JL, Ribera H, Pérez-Páramo M. Efficacy and safety of pregabalin for postoperative pain after total hip and knee arthroplasty: a systematic review and meta-analysis.. Journal of orthopaedic surgery and research. 2025. doi:10.1186/s13018-025-05675-6

4. Robin F, Newman N, Garneau S, Roy M. PROSPECT guidelines for total hip arthroplasty: a systematic review and procedure‐specific postoperative pain management recommendations. Anaesthesia. 2021. doi:10.1111/anae.15541

5. Zhang F, Wang L, Chen Z, Cao X, Chen B. Cognitive behavioral therapy achieves better benefits in relieving postoperative pain and improving joint function: A systematic review and meta-analysis of randomized controlled trials.. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association. 2024. doi:10.1016/j.jos.2023.01.007

6. Juhl CB, Christensen R, Roos EM, Zhang W, Lund H. Impact of Exercise Type and Dose on Pain and Disability in Knee Osteoarthritis: A Systematic Review and Meta‐Regression Analysis of Randomized Controlled Trials. Arthritis & Rheumatology. 2013. doi:10.1002/art.38290